Effects of Febuxostat Therapy on Circulating Adipokine Profiles in Patients with Overweight or Obesity and Asymptomatic Hyperuricemia: A Randomized Controlled Study

Meijuan Dong; Zhaohui Cui; Yuanyuan Liu; Yanlong Bu; Kun An; Li Mao

doi:10.1159/000540701

Obesity Facts (Aug 2024)

Effects of Febuxostat Therapy on Circulating Adipokine Profiles in Patients with Overweight or Obesity and Asymptomatic Hyperuricemia: A Randomized Controlled Study

Meijuan Dong,
Zhaohui Cui,
Yuanyuan Liu,
Yanlong Bu,
Kun An,
Li Mao

Affiliations

Meijuan Dong: Department of Endocrinology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China
Zhaohui Cui: Department of Endocrinology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China
Yuanyuan Liu: Department of Endocrinology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China
Yanlong Bu: Department of Endocrinology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China
Kun An: Department of Neurology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China
Li Mao: Department of Endocrinology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China

DOI: https://doi.org/10.1159/000540701

Abstract

Read online

Introduction: Elevated levels of serum uric acid (SUA) are strongly associated with several components of the metabolic syndrome, particularly obesity. Previous studies have reported the correlation between SUA levels, xanthine oxidoreductase (XOR) activity, and the imbalanced adipokine levels that are characteristic of obesity. In this study, we explored the effect of febuxostat on circulating adipokine profiles in patients with overweight or obesity and asymptomatic hyperuricemia. Methods: This study was a single-center, randomized, and controlled clinical trial that enrolled 130 participants with asymptomatic hyperuricemia and obesity. One hundred seventeen participants were included in the final analysis, with 60 participants in the febuxostat group and 57 in the control group. We compared the circulating adipokine levels at 3 and 6 months, including high molecular weight (HMW) adiponectin, chemerin, omentin, monocyte chemotactic protein-1, asprosin, fibroblast growth factor 21, neuregulin-4, leptin, resistin, vaspin, visfatin, adipsin, and assessed the correlation between changes in adipokine levels (Δadipokines) and changes in XOR activity (ΔXOR) after febuxostat treatment. Results: The results showed that an increase in HMW adiponectin and omentin levels and a decrease in chemerin and asprosin levels at 3 or 6 months compared to the control group. Additionally, a positive correlation was observed between ΔXOR activity and Δasprosin. Furthermore, after adjusting for triglyceride (ΔTG) and serum uric acid (ΔSUA) in multiple linear regression analyses, we found that ΔXOR activity was independently correlated with Δasprosin. Conclusion: This study may provide important evidence that febuxostat could alleviate the imbalance in circulating adipokine levels in patients with overweight or obesity and asymptomatic hyperuricemia. Furthermore, we observed a positive correlation between changes in asprosin levels and changes in XOR activity after febuxostat treatment.

Published in Obesity Facts

ISSN: 1662-4025 (Print); 1662-4033 (Online)
Publisher: Karger Publishers
Country of publisher: Switzerland
LCC subjects: Technology: Home economics: Nutrition. Foods and food supply; Medicine: Internal medicine: Specialties of internal medicine: Nutritional diseases. Deficiency diseases
Website: http://www.karger.com/ofa

About the journal

Abstract

Keywords